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Colonization resistance refers to the ability of the colonic microbiota to prevent invasion by pathogens
including Clostridium difficile. In a recent article, Buffie et al. (2014) have demonstrated that a single meta-
bolic cluster present in the normal, colonic microflora is responsible for preventing C. difficile invasion of
healthy hosts.Infections caused by Clostridium difficile,
a Gram-positive, spore-forming, strict
anaerobe, have risen dramatically over
the past decade. The colonic microflora
normally provides protection against
invading pathogens. However, treatment
of patients with broad-spectrum antibi-
otics often leads to ‘‘collateral damage’’
to the microflora, thus leaving an opening
to C. difficile infection (CDI). Conven-
tional treatment of CDI is with antibiotics
such as vancomycin, metronidazole, or
fidaxomicin (Koenigsknecht and Young,
2013). While these antibiotics prevent
C. difficile growth, they have no effect
on spores, and their use prevents full
reconstitution of the normal microflora.
Thus, due to the continued presence
of antibiotic-resistant spores in the colon
and the environment, treated patients
frequently relapse with CDI (Tannock
et al., 2010).
Endospores are dormant forms of
bacteria that are resistant to multiple
environmental stresses. Upon receiving
appropriate environmental signals, these
spores germinate and resume active,
vegetative growth.C. difficile spore germi-
nation is triggered by a mixture of glycine
(Sorg and Sonenshein, 2008) and certain
bile acids (e.g., taurocholic acid)—small,
amphipathic, cholesterol-based com-
pounds that aid in the absorption of fats
and cholesterol during digestion.
Upon entry into the colonic environ-
ment, bile acids are modified through
two processes. First, bile salt hydrolases
(BSHs), which are expressed on the
surfaces of many colonic commensals,
enzymatically cleave the conjugated
amino acid from the steroid core (e.g.,
taurocholic acid is cleaved to taurine +
cholic acid) (Ridlon et al., 2006). The sec-ond process is performed by the products
of a metabolic cluster present in only a
small subset of the colonic microbiota.
These organisms actively take up decon-
jugated bile acids and, through a series of
enzymatic steps, remove the 7a-hydroxyl
group (e.g., cholic acid is converted to
deoxycholic acid) (Figure 1) (Ridlon
et al., 2006). The actions of these bacteria
lead to the complete conversion of
the host-derived bile acids (primary bile
acids) to secondary bile acids (Ridlon
et al., 2006; Theriot et al., 2014).
Previous studies have indicated that
secondary bile acids, specifically deoxy-
cholic acid, are inhibitors of C. difficile
vegetative cell growth under laboratory
conditions, leading to the hypothesis
that the microbial conversion of cholic-
to-deoxycholic acid in the gut creates
an environment that is refractory to
C. difficile vegetative growth (Sorg and
Sonenshein, 2008; Wilson, 1983). In fact,
changes in the colonic microbial popula-
tion that occur upon antibiotic treatment
abolish the ability to 7a-dehydroxylate
bile acids and lead to a concomitant
increase in the abundance of primary
bile acids that induce germination by
C. difficile spores (Figure 1) (Theriot
et al., 2014). Furthermore, these primary
bile acids are not toxic to vegetative
C. difficile (Sorg and Sonenshein, 2008).
Now, in a recent article published
in Nature, Buffie and colleagues (Buffie
et al., 2014) provide evidence that a single
metabolic cluster present in healthymicro-
flora correlates with protection against
C. difficile invasion. By analyzing those
bacteria that are present in the human
and mouse colonic environment of
C. difficile-sensitive and -resistant individ-
uals, the authors conclude that the pres-Cell Host & Microbe 16, Nence of a metabolic cluster capable of
7a-dehydroxylation of primary bile acids
correlates with protection against CDI.
They then show that colonizing mice with
Clostridium scindens, a bacterium that is
capable of 7a-dehydroxylation of primary
bile acids, protects against CDI.
C. difficile, a member of Clostridium
cluster XI, does not 7a-dehydroxylate
bile acids. In contrast, C. scindens,
belonging to cluster XIVa, does, and its
bile acid 7a-dehydroxylation pathway
has been studied in detail (Ridlon et al.,
2006). Though C. scindens and other bile
acid-metabolizing bacteria completely
convert the primary bile acids that enter
the colonic environment to secondary
bile acids, their numbers in the colonic
environment are low compared to other
organisms. Furthermore, they appear to
be sensitive to vancomycin and metroni-
dazole, which are frequently used to treat
CDI in patients. Interestingly, fidaxomicin
does not inhibit growth of cluster XIVa
Clostridia (Tannock et al., 2010), and
fidaxomicin-treated patients have a lower
recurrence rate than do patients treated
with vancomycin or metronidazole.
The present study is a major leap
forward in defining the mechanisms of
colonization resistance and uses the
mouse model of C. difficile infection that
has gained popularity for the study
of CDI. While mice express similar bile
acids as humans, they also synthesize
muricholic acids, which are not found in
humans. Muricholic acids inhibit germina-
tion by C. difficile spores and also inhibit
C. difficile vegetative growth with similar
MIC values as deoxycholic acid (Francis
et al., 2013). Thus, it is unclear why the
bacteria capable of 7a-dehydroxylation
are needed to protect mice againstovember 12, 2014 ª2014 Elsevier Inc. 551
Figure 1. C. scindens 7a-dehydroxylation Prevents C. difficile Growth
Upon entry into the colonic environment, the 7a-hydroxyl group on cholic acid is removed to produce deoxycholic acid by selectmembers of the colonic microbiota,
includingC. scindens (Ridlon et al., 2006). Deoxycholic acid inhibitsC. difficile vegetative growth (Sorg and Sonenshein, 2008). During antibiotic treatment, the organ-
isms that 7a-dehydroxylate bile acids are killed, leading to an increased abundance of cholic acid derivatives in the colonic environment (Theriot et al., 2014). These
compounds, in combination with glycine (Sorg and Sonenshein, 2008), germinateC. difficile spores, which can then grow out as vegetative cells and cause disease.
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inhibitory molecules are present in the
colonic environment. Additional studies
using organisms with bile acid profiles
more similar to those of humanswill clarify
these issues. For example, the Syrian
hamster synthesizes a bile acid spectrum
that is similar to humans and has been
used as a model of C. difficile infection
for 35 years.
Bile acids are clearly important for
germination by C. difficile spores in the
laboratory—and possibly in the host
(Giel et al., 2010; Sorg and Sonenshein,
2008; Theriot et al., 2014). However, while
it is assumed that cholic acid derivatives
are actual in vivo germinants for
C. difficile spores, this has not been
convincingly demonstrated. Furthermore,
deoxycholic acid has not been con-
clusively shown to be the molecule that
protects against CDI. The data supporting
the hypotheses that cholic acid is an
in vivo spore germinant and that the
microbial conversion of cholic acid to de-
oxycholic acid by C. scindens is the
mechanism by which C. difficile growth
is inhibited have relied on the use of chole-
styramine as a bile acid-binding polymer
(Buffie et al., 2014; Giel et al., 2010).
Importantly, this polymer functions as a
potent anion exchange resin and has
also been shown to bind vancomycin
(Weiss, 2009). Thus, while cholestyramine552 Cell Host & Microbe 16, November 12, 20has bile acid-binding properties, it cannot
be excluded that, in these studies, it
also binds other proteins and/or mole-
cules to protect against C. difficile inva-
sion or in vitro growth.
In summary, this study represents a
significant finding for C. difficile patho-
genesis, mechanisms of colonization
resistance, and, possibly, new probiotic
therapies to limit recurring infections.
Important in this regard, fecal bacterio-
therapy has gained popularity as an
alternative treatment to antibiotics for
recurring CDI and has a nearly 100%
cure rate (Koenigsknecht and Young,
2013). However, the microbial diversity in
the fecal samples is variable due to the
use of different donors. The Buffie study
raises the possibility that a single bile
acid-metabolizing organism, or a cocktail
of bile acidmetabolizing organisms, could
be used as a probiotic to limit recurring
C. difficile disease. Further studies on
the metabolic conversion of bile acids, or
other compounds, by the colonic micro-
flora will provide a more complete under-
standing of the mechanisms of resistance
against C. difficile colonization.ACKNOWLEDGMENTS
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